NASDAQ:SGMO - Sangamo Therapeutics Stock Price, News, & Analysis

$11.60
-0.55 (-4.53 %)
(As of 07/21/2019 02:09 PM ET)
Today's Range
$11.59
Now: $11.60
$12.16
50-Day Range
$8.75
MA: $10.33
$12.05
52-Week Range
$6.26
Now: $11.60
$19.25
Volume1.25 million shs
Average Volume2.76 million shs
Market Capitalization$1.34 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.98
Sangamo Therapeutics, Inc focuses on translating science into genomic medicines that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger proteins (ZFPs) could be engineered to make zinc finger nucleases (ZFNs), proteins that could be used to modify DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors (ZFP TFs) proteins that can be used to increase or decrease gene expression or gene regulation. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:SGMO
CUSIP80067710
Phone510-970-6000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$84.45 million
Book Value$3.60 per share

Profitability

Net Income$-68,330,000.00
Net Margins-113.03%

Miscellaneous

Employees302
Market Cap$1.34 billion
Next Earnings Date8/14/2019 (Estimated)
OptionableOptionable

Receive SGMO News and Ratings via Email

Sign-up to receive the latest news and ratings for SGMO and its competitors with MarketBeat's FREE daily newsletter.

Sangamo Therapeutics (NASDAQ:SGMO) Frequently Asked Questions

What is Sangamo Therapeutics' stock symbol?

Sangamo Therapeutics trades on the NASDAQ under the ticker symbol "SGMO."

How were Sangamo Therapeutics' earnings last quarter?

Sangamo Therapeutics Inc (NASDAQ:SGMO) issued its quarterly earnings results on Wednesday, May, 8th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.27) by $0.14. The biopharmaceutical company had revenue of $8.07 million for the quarter, compared to the consensus estimate of $27.21 million. Sangamo Therapeutics had a negative return on equity of 24.67% and a negative net margin of 113.03%. View Sangamo Therapeutics' Earnings History.

When is Sangamo Therapeutics' next earnings date?

Sangamo Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, August 14th 2019. View Earnings Estimates for Sangamo Therapeutics.

What price target have analysts set for SGMO?

4 equities research analysts have issued 12 month target prices for Sangamo Therapeutics' shares. Their predictions range from $11.00 to $18.00. On average, they expect Sangamo Therapeutics' share price to reach $13.3333 in the next year. This suggests a possible upside of 14.9% from the stock's current price. View Analyst Price Targets for Sangamo Therapeutics.

What is the consensus analysts' recommendation for Sangamo Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sangamo Therapeutics in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Sangamo Therapeutics.

What are Wall Street analysts saying about Sangamo Therapeutics stock?

Here are some recent quotes from research analysts about Sangamo Therapeutics stock:
  • 1. According to Zacks Investment Research, "Sangamo Therapeutics, Inc. is a biotechnology company. It focuses on research and development of genomic therapies as well as develops medicines for patient with genetic diseases. The Company's product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. Sangamo Therapeutics Inc., formerly known as Sangamo BioSciences Inc., is based in Richmond, United States. " (7/17/2019)
  • 2. Wedbush analysts commented, "Neurocrine and collaborator Abbvie announced approval of Orilissa (elagolix) for the management of moderate to severe pain associated with Endometriosis. Abbvie is guiding for the drug to be available in early August. According to Neurocrine mgmt, WAC price is $844.87/ mo for both 150mg QD regimen and 200mg BID regimen. Max treatment duration is 24mo for former and 6mo for latter. We are not making any material changes to our Orilissa sales ests. Neurocrine is entitled to a $40M approval milestone payment in 3Q18 and tiered royalties, which we believe range from 16-20%. Reiterate BUY." (7/24/2018)

Has Sangamo Therapeutics been receiving favorable news coverage?

News headlines about SGMO stock have been trending neutral on Sunday, according to InfoTrie Sentiment. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Sangamo Therapeutics earned a news impact score of 0.3 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Sangamo Therapeutics.

Who are some of Sangamo Therapeutics' key competitors?

What other stocks do shareholders of Sangamo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sangamo Therapeutics investors own include NVIDIA (NVDA), Brainstorm Cell Therapeutics (BCLI), Novavax (NVAX), Alibaba Group (BABA), Advanced Micro Devices (AMD), Micron Technology (MU), Celgene (CELG), Gilead Sciences (GILD), Zuora (ZUO) and Crispr Therapeutics (CRSP).

Who are Sangamo Therapeutics' key executives?

Sangamo Therapeutics' management team includes the folowing people:
  • Dr. Alexander D. Macrae, CEO, Pres & Director (Age 56)
  • Ms. Kathy Y. Yi, EVP, CFO, Principal Accounting Officer & Sec. (Age 47)
  • Dr. Edward R. Conner, Sr. VP & Chief Medical Officer (Age 46)
  • Dr. Edward Rebar, Sr. VP & CTO
  • Mr. McDavid Stilwell, VP of Corp. Communications & Investor Relations

Who are Sangamo Therapeutics' major shareholders?

Sangamo Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Edge Wealth Management LLC (0.06%) and Commonwealth Equity Services LLC (0.01%). Company insiders that own Sangamo Therapeutics stock include Curt A Herberts III, Edward R Conner, H Stewart Parker, Kathy Yi, Saira Ramasastry, Steven J Mento and William R Ringo. View Institutional Ownership Trends for Sangamo Therapeutics.

Which major investors are selling Sangamo Therapeutics stock?

SGMO stock was sold by a variety of institutional investors in the last quarter, including Edge Wealth Management LLC and Commonwealth Equity Services LLC. Company insiders that have sold Sangamo Therapeutics company stock in the last year include Edward R Conner and Kathy Yi. View Insider Buying and Selling for Sangamo Therapeutics.

How do I buy shares of Sangamo Therapeutics?

Shares of SGMO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sangamo Therapeutics' stock price today?

One share of SGMO stock can currently be purchased for approximately $11.60.

How big of a company is Sangamo Therapeutics?

Sangamo Therapeutics has a market capitalization of $1.34 billion and generates $84.45 million in revenue each year. The biopharmaceutical company earns $-68,330,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis. Sangamo Therapeutics employs 302 workers across the globe.View Additional Information About Sangamo Therapeutics.

What is Sangamo Therapeutics' official website?

The official website for Sangamo Therapeutics is http://www.sangamo.com/.

How can I contact Sangamo Therapeutics?

Sangamo Therapeutics' mailing address is 501 CANAL BLVD, RICHMOND CA, 94804. The biopharmaceutical company can be reached via phone at 510-970-6000 or via email at [email protected]


MarketBeat Community Rating for Sangamo Therapeutics (NASDAQ SGMO)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  346 (Vote Outperform)
Underperform Votes:  331 (Vote Underperform)
Total Votes:  677
MarketBeat's community ratings are surveys of what our community members think about Sangamo Therapeutics and other stocks. Vote "Outperform" if you believe SGMO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SGMO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel